Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management".

Scilex Pharmaceuticals Sorrento Therapeutics
click
Semnur
Pharmaceuticals™
Getting Back to Normal

Menu

Skip to content
  • About
  • Management
  • Chronic Back Pain
  • Clinical Study
  • News
  • Contact
Search
Semnur Pharmaceuticals

News

Scilex Semnur Corporate Presentation

April 15, 2019

Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program

March 27, 2019

Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

March 22, 2019

Semnur Pharmaceuticals Begins Pivotal Phase 3 Trial For SP-102 In Patients With Lumbar Radicular Pain/Sciatica

January 07, 2018

Semnur Pharmaceuticals, Inc., Announces Successful Phase 1 / 2 Trial in Patients with Radicular Pain for Its Lead Product, SP-102

June 26, 2017

Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management Pipeline

August 15, 2016

Top 30 Life Science Startups To Watch In The U S

October 23, 2014

TiE50 Awards Program 2014 Winners Includes Semnur Pharmaceuticals

May 16, 2014
  • Contact
  • Privacy Policy
  • Terms of Use
©2023 Semnur Pharmaceuticals, Inc.
All rights reserved.
Semnur Pharmaceuticals, Inc. is being acquired by Scintilla Pharmaceuticals, Inc.
Visit Scintilla Pharmaceuticals, Inc. Go To Semnur Pharmaceuticals